CymaBay Therapeutics (CymaBay Therapeutics) 6-1 Month Momentum % : 125.07% (As of May. 16, 2024)

View and export this data going back to 2014. Start your Free Trial

What is CymaBay Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-16), CymaBay Therapeutics's 6-1 Month Momentum % is 125.07%.

The industry rank for CymaBay Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

CBAY's 6-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -2.35 vs CBAY: 125.07

Competitive Comparison of CymaBay Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, CymaBay Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CymaBay Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CymaBay Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where CymaBay Therapeutics's 6-1 Month Momentum % falls into.

CymaBay Therapeutics (NAS:CBAY) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CymaBay Therapeutics (NAS:CBAY) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

CymaBay Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of CymaBay Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

CymaBay Therapeutics (CymaBay Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CymaBay Therapeutics Inc (NAS:CBAY) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

C0I:Germany

Address

7575 Gateway Boulevard, Suite 110, Newark, CA, USA, 94560

Website

https://www.cymabay.com

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).

Executives

Charles Mcwherter	officer: Chief Scientific Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Daniel Menold	officer: Vice President, Finance	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Paul T Quinlan	officer: General Counsel	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Janet Dorling	director	C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Sujal Shah	director, officer: Chief Executive Officer	C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560
Kurt Von Emster	director	601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Harish Shantharam	officer: Chief Financial Officer	7575 GATEWAY BLVD, NEWARK CA 94560
Dennis D Kim	officer: Chief Medical Officer	C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803
Eric Lefebvre	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Thomas G Wiggans	director
Lewis J Stuart	officer: Chief Commercial Officer	3172 PORTER DRIVE, PALO ALTO CA 94304
Venbio Select Advisor Llc	10 percent owner	110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Behzad Aghazadeh	10 percent owner	C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Carl Goldfischer	director	161 WEST 61ST STREET, NEW YORK NY 10022
Robert James Wills	director	175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103